Interferon for HBV is a blockbuster indication worldwide.
There’s a lot of use in China and Southeast Asia, where HBV is a serious problem, the markets are saturated with dirt-cheap interferon generics from multiple vendors, and much of the populace cannot afford to pay a premium price for such branded drugs as Baraclude. Bottom line: No one is making consequential money from selling interferon for HBV, and BMY won’t be able to either, IMO.
Market Data 
Markets 
AI
